Immunoprecise Antibodies Ltd (NASDAQ:IPA), together with InterSystems, have collaborated to integrate the new vector search capability of the InterSystems IRIS data platform with Immunoprecise subsidiary BioStrand’s LENSai platform for AI-driven applications in healthcare and life sciences.
The partnership between InterSystems and Immunoprecise Antibodies marks a significant step forward in tackling the growing data challenges in healthcare and life sciences.
As the global AI market is forecasted to surpass $1.3 trillion by 2032, this collaboration underscores both companies’ dedication to innovation and solution development.